Cellares is an Integrated Development and Manufacturing Organization (IDMO) - a category it claims to have pioneered - focused on automating the development and large-scale manufacturing of cell therapies. The company applies Industry 4.0 approaches to what has historically been a manual, costly, and failure-prone process, with the stated aim of accelerating drug development, reducing costs, and improving patient access to cell-based treatments.
Its core technology stack centres on three integrated components: the Cell Shuttle™, a modular, cGMP-compliant platform designed to deliver end-to-end automation for industrial-scale cell therapy manufacturing; Cell Q™, an automated quality control system built to work alongside the manufacturing platform; and an integrated software suite that ties both hardware systems together across manufacturing operations. Together, these form the backbone of what Cellares calls its Smart Factory model.
The company currently operates Smart Factories in South San Francisco and Bridgewater, with expansion into Europe and Japan planned. Its partners span academic institutions, biotechs, and pharmaceutical companies - organizations that use its IDMO platform to develop and manufacture cell therapies at scale rather than building that infrastructure independently.
The team draws on industry experience across cell therapy development, bioprocess automation, cGMP manufacturing systems, and manufacturing software. The company's orientation is collaborative and mission-driven, oriented around reducing the technical and economic barriers that have constrained cell therapy manufacturing to date.